Palmitoylethanolamide (PEA)
One of the better meta-analysis-backed pain supplements available
Palmitoylethanolamide (PEA) is a fatty acid amide the body already produces on its own, in higher amounts specifically at sites of tissue injury and inflammation — it's part of the body's own built-in pain-and-inflammation regulation system. It works mainly through PPAR-alpha receptors and by calming overactive mast cells, rather than blocking pain signals directly the way an opioid or NSAID does.
PEA gets grouped with cannabinoids in a lot of marketing because it interacts with a related receptor system, but it doesn't bind cannabinoid receptors and has no psychoactive effect. What sets it apart from most trendy pain ingredients is the depth of the human evidence: a substantial meta-analysis pooling over a dozen randomized controlled trials, plus individual trials in specific pain conditions like knee osteoarthritis and diabetic neuropathy.
Chronic Pain Reduction
A 2023 meta-analysis of 11 double-blind RCTs in 774 patients found PEA produced a large, statistically significant reduction in pain scores compared to placebo or active comparators, with no major reported side effects across the pooled trials.
Knee Osteoarthritis
A dedicated randomized, placebo-controlled trial in 111 adults with knee osteoarthritis found significant WOMAC pain score reductions at both 300mg and 600mg daily doses over 8 weeks compared to placebo.
Diabetic Neuropathic Pain
A randomized controlled trial in adults with diabetes-related peripheral neuropathic pain found significant reductions in both total pain scores and specific neuropathic pain sub-scores after 8 weeks of 600mg daily PEA versus placebo.
Favorable Safety Profile
Because it's a compound the body already produces, PEA has consistently shown a clean safety record across trials, with no major adverse events attributed to it in the pooled meta-analysis data.
- Give it at least 4-8 weeks — PEA tends to build effect gradually rather than acting like an immediate painkiller
- Micronized/ultra-micronized forms are absorbed meaningfully better than standard PEA powder
- Take with a meal containing fat, since PEA is fat-soluble
- Doesn't replace prescribed pain management — discuss with your doctor before reducing other medications
A 2023 systematic review and meta-analysis in Nutrients identified 11 double-blind randomized controlled trials of PEA for chronic pain, covering 774 patients, and found a large pooled effect favoring PEA over placebo or active comparators (standardized mean difference 1.68), with several individual trials also reporting improved quality of life and no major safety concerns. A separate 8-week RCT in 70 adults with diabetic peripheral neuropathic pain found 600mg daily PEA significantly reduced both overall pain and neuropathic pain sub-scores compared to placebo.
How PEA Compares
| Ingredient | Best For | Key Difference |
|---|---|---|
| PEA | Chronic Pain, Neuropathic Pain | Endogenous compound; large meta-analysis behind it |
| Turmeric/Curcumin | Inflammation, Joint Pain | Requires enhanced-absorption forms; different mechanism |
| Boswellia | Joint Inflammation | Inhibits 5-LOX enzyme; more joint-specific evidence |
| Bromelain | Digestion, Mild Inflammation | Enzyme-based; less evidence specifically for chronic/neuropathic pain |
These are the most common comparisons our customers ask about in-store.
1. Lang-Illievich, K., Klivinyi, C., Lasser, C., Brenna, C.T.A., Szilagyi, I.S., Bornemann-Cimenti, H. (2023). Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients, 15(6), 1350.
2. Pickering, E., Steels, E.L., Steadman, K.J., Rao, A., Vitetta, L. (2022). A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology.
3. Steels, E., Venkatesh, R., Steels, E., Vitetta, G., Vitetta, L. (2019). A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology, 27, 475–485.
All references are peer-reviewed studies or position stands from reputable organizations.
Related Ingredients
Get Your Free Supplement Guide
“50 Supplement Myths Debunked” PDF + weekly evidence-based tips. 100% free.
Get Your Free PDF →No spam, ever. Unsubscribe anytime.